Assessing the Adjuvant Potential of Chinese Hamster Ovary Host Cell Proteins Using an In Vitro Dendritic Cell Assay
Biotechnology and Bioengineering · 2025-05 · 122 (5) · 1105-1117
DOI: 10.1002/bit.28950 ↗At a glance
Journal article in Biotechnology and Bioengineering, published online on 2025-02-10. Written by Sherin Panikulam and 8 co-authors. Institution: Institute of Pharma Technology, University of Applied Sciences Northwestern Switzerland, Muttenz, Switzerland. Major MEDLINE topics: Dendritic Cells, Adjuvants, Immunologic. Cited 10 times so far (Crossref); 58 references. The full text is freely available (open access, CC BY 4.0). Funded by: This research was supported by Novartis Pharma AG..
Abstract (original language)
Host cell proteins (HCPs) are process‐related impurities of therapeutic protein production and may affect product quality or patient safety. In clinical trials, certain HCPs (e.g., PLBL2 or CCL2) that co‐purify with the therapeutic protein have been associated with immune reactions in patients. In this study, we examined the adjuvant potential of six commonly detected HCPs from CHO cells (PRDX1, S100A4, PLBL2, CCL2, CLU, and YWHAE) using an in vitro dendritic cell (DC) maturation assay. Recombinant HCPs were expressed in CHO cells to mimic manufacturing conditions. PRDX1, S100A4, and PLBL2 caused a slight increase in the expression of maturation markers on DCs, while YWHAE, CLU, and CCL2 did not. Interestingly, CLU and CCL2 reduced the DC maturation induced by rituximab. In addition, we observed that process parameters such as elution conditions during chromatographic purification can influence HCP aggregation, which in turn can mask or enhance the intrinsic adjuvant potential of an HCP. These findings not only provide initial insights into the adjuvant potential of individual HCPs but also indicate that the quantity as well as the degree of aggregation of HCPs might influence adjuvanticity.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute of Pharma Technology, University of Applied Sciences Northwestern Switzerland, Muttenz, Switzerland.
- Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
- Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
- Technical Research and Development, Novartis Pharma AG, Basel, Switzerland.
ORCID profiles: Hannah Morgan, Michael Gutknecht, Anette Karle, Oliver Anderka, Nicolas Lebesgue, Thomas K Villiger
Funding
- This research was supported by Novartis Pharma AG.
Cite
APA
Panikulam, S., Morgan, H., Gutknecht, M., Karle, A., Rajaratnam, A., Muntwyler, J., Anderka, O., Lebesgue, N., & Villiger, T. K. (2025). Assessing the Adjuvant Potential of Chinese Hamster Ovary Host Cell Proteins Using an In Vitro Dendritic Cell Assay. Biotechnology and Bioengineering, 122(5), 1105-1117. https://doi.org/10.1002/bit.28950
Vancouver
Panikulam S, Morgan H, Gutknecht M, Karle A, Rajaratnam A, Muntwyler J, et al. Assessing the Adjuvant Potential of Chinese Hamster Ovary Host Cell Proteins Using an In Vitro Dendritic Cell Assay. Biotechnology and Bioengineering. 2025;122(5):1105-1117. doi:10.1002/bit.28950
BibTeX
@article{Panikulam2025,
author = {Panikulam, Sherin and Morgan, Hannah and Gutknecht, Michael and Karle, Anette and Rajaratnam, Atchaya and Muntwyler, Jennifer and Anderka, Oliver and Lebesgue, Nicolas and Villiger, Thomas K},
title = {Assessing the Adjuvant Potential of Chinese Hamster Ovary Host Cell Proteins Using an In Vitro Dendritic Cell Assay},
journal = {Biotechnology and Bioengineering},
year = {2025},
volume = {122},
number = {5},
pages = {1105--1117},
doi = {10.1002/bit.28950}
}
EUVIMED